Long-term treatment with Austedo (deutetrabenazine) safely led to sustained reductions in chorea for people with Huntington’s disease, including those…
Articles by Lindsey Shapiro, PhD
A data safety monitoring committee has recommended that enrollment of the highest dosing group resume in the European Phase 1/2…
A single injection of Wave Life Science‘s experimental therapy WVE-003 was found, at either of the two lowest tested…
Social support for children of a parent with Huntington’s disease from someone other than a caregiver is important in…
A Phase 2 trial of pepinemab failed to significantly improve certain cognitive abilities in people with prodromal to early…
AMT-130, uniQure’s investigational gene therapy for Huntington’s disease, was generally well-tolerated and led to reductions in the levels…
The first two dosing groups in a Phase 1/2 trial of AMT-130, uniQure’s investigational gene therapy for Huntington’s…